BOK Financial Private Wealth Inc. Invests $29,000 in Amgen Inc. (NASDAQ:AMGN)

BOK Financial Private Wealth Inc. acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 100 shares of the medical research company’s stock, valued at approximately $29,000.

Several other large investors have also recently bought and sold shares of AMGN. Southland Equity Partners LLC raised its position in shares of Amgen by 2.3% during the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock valued at $443,000 after acquiring an additional 34 shares during the last quarter. Acropolis Investment Management LLC increased its position in shares of Amgen by 3.5% in the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock valued at $288,000 after buying an additional 34 shares in the last quarter. Opal Wealth Advisors LLC increased its position in shares of Amgen by 1.9% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after buying an additional 34 shares in the last quarter. FORVIS Wealth Advisors LLC increased its position in shares of Amgen by 1.4% in the 4th quarter. FORVIS Wealth Advisors LLC now owns 2,578 shares of the medical research company’s stock valued at $743,000 after buying an additional 35 shares in the last quarter. Finally, Evanson Asset Management LLC increased its position in shares of Amgen by 2.1% in the 4th quarter. Evanson Asset Management LLC now owns 1,666 shares of the medical research company’s stock valued at $480,000 after buying an additional 35 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $265.51 on Tuesday. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $329.72. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The stock has a market capitalization of $142.29 billion, a price-to-earnings ratio of 21.26, a price-to-earnings-growth ratio of 2.53 and a beta of 0.58. The company’s 50 day simple moving average is $279.63 and its 200 day simple moving average is $281.52.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. During the same quarter last year, the business posted $4.09 earnings per share. The company’s quarterly revenue was up 19.8% on a year-over-year basis. As a group, research analysts predict that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.39%. Amgen’s dividend payout ratio is currently 72.06%.

Analyst Ratings Changes

A number of analysts recently commented on the stock. StockNews.com cut shares of Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. The Goldman Sachs Group increased their price objective on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Morgan Stanley cut their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $329.00 target price on shares of Amgen in a research note on Wednesday, April 3rd. Finally, Oppenheimer restated an “outperform” rating and set a $350.00 price objective on shares of Amgen in a research report on Thursday, February 1st. Ten research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $295.30.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.